EVE Health Group (ASX:EVE) said it started stability testing for its treatment candidates for erectile dysfunction and dysmenorrhea, according to a Monday Australian bourse filing.
The treatment candidates are in oral formulations, developed by Nextract.
Results from the testing will form a component of the technical dossier submitted to the Therapeutic Goods Administration, the filing said.
The company plans to submit both products for review in the coming months, and it expects to receive approvals before the end of the current year, per the filing. It completed registration with the Therapeutic Goods Administration as both a registered sponsor and a registered manufacturer.
EVE Health Group's acquisition of Nextract is expected to be completed on or around June 12, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.